Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
02/2003
02/27/2003WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003WO2003015794A1 Methods and compositions for treating apoptosis associated disorders
02/27/2003WO2003015793A1 Delayed and sustained drug release
02/27/2003WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
02/27/2003WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
02/27/2003WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
02/27/2003WO2003015773A2 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
02/27/2003WO2003015770A1 Novel combination
02/27/2003WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
02/27/2003WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
02/27/2003WO2003015717A2 Tyrosine kinase inhibitors
02/27/2003WO2003015699A2 Topical compositions and methods for treating pain
02/27/2003WO2003015698A2 Application of lipid vehicles and use for drug delivery
02/27/2003WO2003015690A2 Method for treating primary insomnia
02/27/2003WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms
02/27/2003WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
02/27/2003WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes
02/27/2003WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
02/27/2003WO2002098278A3 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
02/27/2003WO2002097046A3 B7 related protein-2 molecules and uses thereof
02/27/2003WO2002094180A3 Pharmaceutically active isoindoline derivatives
02/27/2003WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors
02/27/2003WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists
02/27/2003WO2002089749A3 Arylsulfonamide ethers, and methods of use thereof
02/27/2003WO2002089740A3 Sulfonamides
02/27/2003WO2002087511A3 Modulators of elastase inhibitor secretion
02/27/2003WO2002072542A3 Ph-dependent nmda receptor antagonists
02/27/2003WO2002066420A3 Tryptase inhibitors
02/27/2003WO2002064590A3 Carboline derivatives
02/27/2003WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
02/27/2003WO2002060374A3 Benz-1,3-azole derivatives and their uses as heparanase inhibitors
02/27/2003WO2002058717A3 Methods for treating rheumatoid arthritis using il-17 antagonists
02/27/2003WO2002050054A3 Process for the production of tocotrienols
02/27/2003WO2002046193A3 Heterocyclic ether substituted imidazoquinolines
02/27/2003WO2002028865A3 Condensed pyridoindole derivatives
02/27/2003WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
02/27/2003WO2002020768A3 Caveolin peptides and their use as therapeutics
02/27/2003WO2002000691A3 Polynucleotides and polypeptides encoded thereby
02/27/2003WO2001098471A3 Human phosphodiesterases
02/27/2003WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
02/27/2003WO2001092892A3 Methods to identify compounds that modulate rage
02/27/2003US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection
02/27/2003US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof
02/27/2003US20030040606 Reducing immunogenicities of immunoglobulins by framework-patching
02/27/2003US20030040541 Administering bismuth subgallate to inhibit the production of nitric oxide synthases (NOS)
02/27/2003US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease
02/27/2003US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity
02/27/2003US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases
02/27/2003US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
02/27/2003US20030040509 Methods and compositions for treating diseases associated with excesses in ACE
02/27/2003US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation
02/27/2003US20030040083 Dual specificity antibodies and methods of making and using
02/27/2003US20030040044 Anti-dual integrin antibodies, compositions, methods and uses
02/27/2003US20030039999 B7 related protein-2 molecules and uses thereof
02/27/2003US20030039689 Prodrug in polymer matrix; insertion into body
02/27/2003US20030039687 Using Carbomer
02/27/2003US20030039684 Preparation of a directly mouldable tabletting auxiliary
02/27/2003US20030039669 Use of a composition containing an effective quantity of at least one chelating agent for partially or totally reducing the symptoms associated with histamine release in the organism
02/27/2003US20030039666 Use of parasitic biological agents for prevention and control of autoimmune diseases
02/27/2003US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption
02/27/2003US20030039629 Espression enhancer for protein synthesis inhibitory genes
02/27/2003CA2493349A1 Delayed and sustained drug release
02/27/2003CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
02/27/2003CA2458648A1 Secreted proteins
02/27/2003CA2458643A1 Nucleic-acid associated proteins
02/27/2003CA2458068A1 Methods and compositions for treating apoptosis associated disorders
02/27/2003CA2457932A1 Sodium channel regulators and modulators
02/27/2003CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
02/27/2003CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis
02/27/2003CA2457461A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
02/27/2003CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003CA2457041A1 Novel combination
02/27/2003CA2456988A1 Gas microsphere liposome composites
02/27/2003CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms
02/27/2003CA2454083A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
02/27/2003CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors
02/26/2003WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient
02/26/2003WO2002018407A2 Antisense oligonucleotides against vanilloid receptor 1
02/26/2003EP1286165A2 Neuropeptide receptor and uses thereof
02/26/2003EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
02/26/2003EP1285916A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels
02/26/2003EP1285661A1 Antioxidant and skin preparations for external use
02/26/2003EP1285657A2 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
02/26/2003EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
02/26/2003EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators
02/26/2003EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof
02/26/2003EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
02/26/2003EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators
02/26/2003EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion
02/26/2003EP1284967A1 3-substituted isoquinolin-1-yl derivatives
02/26/2003EP1284961A1 Glycinamides
02/26/2003EP1284959A1 Compounds for modulating the rage receptor
02/26/2003EP1284956A1 Il-8 receptor antagonists
02/26/2003EP1284952A1 Substituted chalcones as therapeutic compounds
02/26/2003EP1284771A1 Aerosol container for formulations of salmeterol xinafoate
02/26/2003EP1284747A2 Compositions and methods for achieving immune suppression
02/26/2003EP1284744A1 Antimigraine combination comprising sapindus and emblica extracts
02/26/2003EP1284740A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono- and disaccharide-based compounds
02/26/2003EP1284736A2 Opioid antagonist compositions and dosage forms
1 ... 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 ... 1272